AcornMed Biotechnology Co., Ltd. (AcornMed), a precision drugs group that makes a speciality of the testing and evaluation of strong and blood tumors, introduced at the moment that they are going to incorporate Twist Bioscience subsequent era sequencing (NGS) goal enrichment and library preparation panels into AcornMed’s portfolio of exams designed to offer perception into the genetic predisposition and therapy regimens for sufferers, offering a extra focused therapeutic method.
“The partnership between Twist and AcornMed gives us with entry to the worldwide chief in prime quality DNA synthesis at scale and high quality. Twist understands the significance of panel efficiency and consistency when utilizing genetic evaluation to tell scientific therapy,” stated Dr. Feng Lou, CTO and co-founder of AcornMed. “As NGS testing turns into a extra mainstream, and extensively adopted expertise to allow precision drugs, we imagine AcornMed’s merchandise will likely be extensively embraced to positively remodel affected person therapy and drive down the related prices of well being economics in China.”
“Twist Bioscience’s proprietary DNA manufacturing course of and high quality management will play an more and more vital function within the growth of in vitro diagnostic (IVD) panels, aiding within the adoption of NGS as a precision drugs device. This is among the causes AcornMed chosen Twist,” continued Dr. Lou. “As AcornMed begins to maneuver testing into the IVD area, we will really feel assured that the outcomes will meet and exceed the NMPA’s expectations for affected person evaluation and prognosis.”
“We’re happy to allow AcornMed, an progressive and affected person centered firm, to speed up their mission of offering distinctive precision drugs options for most cancers identification and therapy,” stated Emily Leproust, CEO and co-founder of Twist Bioscience. “The power to stratify sufferers to help in therapy based mostly on their cancers’ genetic make-up represents a essential issue for the way forward for drugs.”
AcornMed Biotechnology Co., Ltd. (AcornMed) is an innovation-driven Nationwide Excessive-Tech Enterprise in China. With the top workplace positioned in Beijing Financial-Technological Growth Space, AcornMed has established two R&D facilities in Beijing and Tianjin, with a complete space of 5,000 sq. Meters.
Primarily based on the self-developed massive information platform for genomic evaluation, AcornMed gives complete resolution of most cancers precision drugs with genomics applied sciences. As a number one subsequent era sequencing (NGS) company in strong tumors and hematological malignancies, AcornMed has constructed a strong model fame in lung most cancers, gastrointestinal tumors, urologic most cancers, leukemia, and lymphoma. Over 30 scientific testing merchandise have been launched and the applying eventualities cowl early detection and screening of a number of cancers, hereditary most cancers identification, companion diagnostics for focused remedy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, and many others. Till now the corporate has served greater than 500 hospitals and obtained commendations from many oncologists and laboratory consultants.
About Twist Bioscience Company
Twist Bioscience is a number one and quickly rising artificial biology and genomics firm that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary expertise that pioneers a brand new technique of producing artificial DNA by “writing” DNA on a silicon chip. Twist is leveraging its distinctive expertise to fabricate a broad vary of artificial DNA-based merchandise, together with artificial genes, instruments for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and growth. Twist can also be pursuing longer-term alternatives in digital information storage in DNA and biologics drug discovery. Twist makes merchandise to be used throughout many industries together with healthcare, industrial chemical substances, agriculture and educational analysis.
Authorized Discover Concerning Ahead-Wanting Statements
This press launch incorporates forward-looking statements. All statements aside from statements of historic details contained herein, together with with out limitation, the power of AcornMed’s portfolio of exams to offer a extra focused therapeutic method, AcornMed’s merchandise turning into extensively embraced and positively reworking affected person therapy and driving down the related prices of well being economics in China and Twist’s proprietary DNA manufacturing course of and high quality management enjoying an more and more vital function within the growth of IVD panels and aiding within the adoption of NGS as a precision drugs device, are forward-looking statements reflecting the present beliefs and expectations of administration made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. Such forward-looking statements contain identified and unknown dangers, uncertainties, and different vital elements which will trigger Twist Bioscience’s precise outcomes, efficiency, or achievements to be materially totally different from any future outcomes, efficiency, or achievements expressed or implied by the forward-looking statements. Such dangers and uncertainties embody, amongst others, the dangers and uncertainties of the power to draw new clients and retain and develop gross sales from current clients; dangers and uncertainties of quickly altering applied sciences and intensive competitors in artificial biology might make the merchandise Twist Bioscience is creating out of date or non-competitive; uncertainties of the retention of a major buyer; dangers of third occasion claims alleging infringement of patents and proprietary rights or in search of to invalidate Twist Bioscience’s patents or proprietary rights; and the danger that Twist Bioscience’s proprietary rights could also be inadequate to guard its applied sciences. For an extra description of the dangers and uncertainties that might trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding Twist Bioscience’s enterprise usually, see Twist Bioscience’s danger elements set forth in Twist Bioscience’s Quarterly Report Kind 10-Q filed with the Securities and Trade Fee on February 9, 2021 and subsequent filings with the SEC. Any forward-looking statements contained on this press launch communicate solely as of the date hereof, and Twist Bioscience particularly disclaims any obligation to replace any forward-looking assertion, whether or not because of new data, future occasions or in any other case.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20210407005951/en/